Novel Long-Acting GLP-2 Analogue, FE 203799 (Apraglutide), Enhances Adaptation and Linear Intestinal Growth in a Neonatal Piglet Model of Short Bowel Syndrome with Total Resection of the Ileum.

Slim GM, Lansing M, Wizzard P, Nation PN, Wheeler SE, Brubaker PL, Jeppesen PB, Wales PW, Turner JM

JPEN. Journal of parenteral and enteral nutrition6 Jan 2019Cited by 35 (Europe PMC)

PMID30614011DOI10.1002/jpen.1500PepBankPUB-30614011

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Safety outcome
In neonatal SBS piglets, apraglutide and saline groups were healthy on day 7.
In plain wordsIn piglets with SBS, apraglutide and saline groups were healthy on day 7.
Peptide
Apraglutide
Outcome
Not applicableGeneral health
Study
pign = 18
neonatal SBS without ileum
Comparator
saline
Outcome group
Adverse events · Whole body
Studied dose
5 mg/kg on days 0 and 4 · subcutaneousAs given in this study (pig).
Source sentences
Summary
On day 7, saline and FE-treated piglets were healthy and gained equivalent weight (P = 0.12).
3 context sentences(design, population, supporting numbers)
Summary · context
Neonatal piglets were randomized to saline (n = 10) vs FE treatment (n = 8).
Summary · context
All piglets underwent 75% intestinal resection with jejunocolic anastomosis and were pair-fed parenteral and enteral nutrition.
Summary · context
Saline and FE (5 mg/kg) treatments were administered subcutaneously on days 0 and 4.
Report a problemFND-3061401101
02AnimalAnimal study (in vivo)Efficacy outcome
In neonatal SBS piglets, weight gain was equivalent with apraglutide and saline on day 7.
In plain wordsIn piglets with SBS, weight gain was similar with apraglutide and saline on day 7.
Peptide
Apraglutide
Outcome
No significant changeWeight gain
Study
pign = 18
neonatal SBS without ileum
Comparator
saline
Outcome group
Body weight · Metabolic and weight
Studied dose
5 mg/kg on days 0 and 4 · subcutaneousAs given in this study (pig).
Source sentences
Summary
On day 7, saline and FE-treated piglets were healthy and gained equivalent weight (P = 0.12).
3 context sentences(design, population, supporting numbers)
Summary · context
Neonatal piglets were randomized to saline (n = 10) vs FE treatment (n = 8).
Summary · context
All piglets underwent 75% intestinal resection with jejunocolic anastomosis and were pair-fed parenteral and enteral nutrition.
Summary · context
Saline and FE (5 mg/kg) treatments were administered subcutaneously on days 0 and 4.
Report a problemFND-3061401102
03AnimalAnimal study (in vivo)Efficacy outcome
In neonatal SBS piglets, apraglutide reduced fecal fat losses versus saline.
In plain wordsIn piglets with SBS, apraglutide reduced fat losses in feces versus saline.
Peptide
Apraglutide
Outcome
DecreaseFecal fat losses
Study
pign = 18
neonatal SBS without ileum
Comparator
saline
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
5 mg/kg on days 0 and 4 · subcutaneousAs given in this study (pig).
Source sentences
Summary
Compared with saline piglets, FE-treated piglets had lower fecal fat (P = 0.043) and energy (P = 0.043) losses and exhibited intestinal lengthening (P = 0.001), greater small-intestinal weight (P = 0.004), longer villus height (P = 0.027), and greater crypt depth (P = 0.054).
3 context sentences(design, population, supporting numbers)
Summary · context
Neonatal piglets were randomized to saline (n = 10) vs FE treatment (n = 8).
Summary · context
All piglets underwent 75% intestinal resection with jejunocolic anastomosis and were pair-fed parenteral and enteral nutrition.
Summary · context
Saline and FE (5 mg/kg) treatments were administered subcutaneously on days 0 and 4.
Report a problemFND-3061401103
04AnimalAnimal study (in vivo)Efficacy outcome
In neonatal SBS piglets, apraglutide reduced fecal energy losses versus saline.
In plain wordsIn piglets with SBS, apraglutide reduced energy losses in feces versus saline.
Peptide
Apraglutide
Outcome
DecreaseFecal energy losses
Study
pign = 18
neonatal SBS without ileum
Comparator
saline
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
5 mg/kg on days 0 and 4 · subcutaneousAs given in this study (pig).
Source sentences
Summary
Compared with saline piglets, FE-treated piglets had lower fecal fat (P = 0.043) and energy (P = 0.043) losses and exhibited intestinal lengthening (P = 0.001), greater small-intestinal weight (P = 0.004), longer villus height (P = 0.027), and greater crypt depth (P = 0.054).
3 context sentences(design, population, supporting numbers)
Summary · context
Neonatal piglets were randomized to saline (n = 10) vs FE treatment (n = 8).
Summary · context
All piglets underwent 75% intestinal resection with jejunocolic anastomosis and were pair-fed parenteral and enteral nutrition.
Summary · context
Saline and FE (5 mg/kg) treatments were administered subcutaneously on days 0 and 4.
Report a problemFND-3061401104
05AnimalAnimal study (in vivo)Efficacy outcome
In neonatal SBS piglets, apraglutide increased intestinal length versus saline.
In plain wordsIn piglets with SBS, apraglutide increased intestinal length versus saline.
Peptide
Apraglutide
Outcome
IncreaseIntestinal length
Study
pign = 18
neonatal SBS without ileum
Comparator
saline
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
5 mg/kg on days 0 and 4 · subcutaneousAs given in this study (pig).
Source sentences
Summary
Compared with saline piglets, FE-treated piglets had lower fecal fat (P = 0.043) and energy (P = 0.043) losses and exhibited intestinal lengthening (P = 0.001), greater small-intestinal weight (P = 0.004), longer villus height (P = 0.027), and greater crypt depth (P = 0.054).
3 context sentences(design, population, supporting numbers)
Summary · context
Neonatal piglets were randomized to saline (n = 10) vs FE treatment (n = 8).
Summary · context
All piglets underwent 75% intestinal resection with jejunocolic anastomosis and were pair-fed parenteral and enteral nutrition.
Summary · context
Saline and FE (5 mg/kg) treatments were administered subcutaneously on days 0 and 4.
Report a problemFND-3061401105
06AnimalAnimal study (in vivo)Efficacy outcome
In neonatal SBS piglets, apraglutide increased small-intestinal weight versus saline.
In plain wordsIn piglets with SBS, apraglutide increased small-intestinal weight versus saline.
Peptide
Apraglutide
Outcome
IncreaseSmall-intestinal weight
Study
pign = 18
neonatal SBS without ileum
Comparator
saline
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
5 mg/kg on days 0 and 4 · subcutaneousAs given in this study (pig).
Source sentences
Summary
Compared with saline piglets, FE-treated piglets had lower fecal fat (P = 0.043) and energy (P = 0.043) losses and exhibited intestinal lengthening (P = 0.001), greater small-intestinal weight (P = 0.004), longer villus height (P = 0.027), and greater crypt depth (P = 0.054).
3 context sentences(design, population, supporting numbers)
Summary · context
Neonatal piglets were randomized to saline (n = 10) vs FE treatment (n = 8).
Summary · context
All piglets underwent 75% intestinal resection with jejunocolic anastomosis and were pair-fed parenteral and enteral nutrition.
Summary · context
Saline and FE (5 mg/kg) treatments were administered subcutaneously on days 0 and 4.
Report a problemFND-3061401106
07AnimalAnimal study (in vivo)Efficacy outcome
In neonatal SBS piglets, apraglutide increased villus height versus saline.
In plain wordsIn piglets with SBS, apraglutide increased intestinal villus height versus saline.
Peptide
Apraglutide
Outcome
IncreaseVillus height
Study
pign = 18
neonatal SBS without ileum
Comparator
saline
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
5 mg/kg on days 0 and 4 · subcutaneousAs given in this study (pig).
Source sentences
Summary
Compared with saline piglets, FE-treated piglets had lower fecal fat (P = 0.043) and energy (P = 0.043) losses and exhibited intestinal lengthening (P = 0.001), greater small-intestinal weight (P = 0.004), longer villus height (P = 0.027), and greater crypt depth (P = 0.054).
3 context sentences(design, population, supporting numbers)
Summary · context
Neonatal piglets were randomized to saline (n = 10) vs FE treatment (n = 8).
Summary · context
All piglets underwent 75% intestinal resection with jejunocolic anastomosis and were pair-fed parenteral and enteral nutrition.
Summary · context
Saline and FE (5 mg/kg) treatments were administered subcutaneously on days 0 and 4.
Report a problemFND-3061401107
08AnimalAnimal study (in vivo)Efficacy outcome
In neonatal SBS piglets, apraglutide-treated animals had greater crypt depth than saline-treated animals, with P = 0.054.
In plain wordsIn piglets with SBS, crypt depth was greater with apraglutide than saline, with P = 0.054.
Peptide
Apraglutide
Outcome
IncreaseCrypt depth
Study
pign = 18
neonatal SBS without ileum
Comparator
saline
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
5 mg/kg on days 0 and 4 · subcutaneousAs given in this study (pig).
Source sentences
Summary
Compared with saline piglets, FE-treated piglets had lower fecal fat (P = 0.043) and energy (P = 0.043) losses and exhibited intestinal lengthening (P = 0.001), greater small-intestinal weight (P = 0.004), longer villus height (P = 0.027), and greater crypt depth (P = 0.054).
3 context sentences(design, population, supporting numbers)
Summary · context
Neonatal piglets were randomized to saline (n = 10) vs FE treatment (n = 8).
Summary · context
All piglets underwent 75% intestinal resection with jejunocolic anastomosis and were pair-fed parenteral and enteral nutrition.
Summary · context
Saline and FE (5 mg/kg) treatments were administered subcutaneously on days 0 and 4.
Report a problemFND-3061401108

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.